Clinical Breast Cancer

Top Research Topics at Clinical Breast Cancer?

Clinical Breast Cancer covers a variety of subjects, including Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Issues in Breast cancer were discussed, taking into consideration concepts from other disciplines like Surgery, Radiation therapy and Radiology. The featured Surgery studies mainly concentrate on Mastectomy but also cover areas of interest in Breast reconstruction.

Studies on Radiology discussed in the journal link to the field of Mammography. The study on Internal medicine presented is investigated in conjunction with research in Gastroenterology. The Oncology works featured in the journal incorporate elements from Taxane, Disease, Hazard ratio, Stage (cooking) and Adjuvant therapy.

The studies in Chemotherapy featured incorporate elements of Neoadjuvant therapy, Regimen and Anthracycline. It addresses concerns in Metastatic breast cancer which are intertwined with other disciplines, such as Phases of clinical research, Neutropenia, Capecitabine, Vinorelbine and Gemcitabine. It emphasizes research on Trastuzumab, which includes concerns such as Lapatinib.

• Breast cancer (95.40%)
• Internal medicine (65.35%)
• Oncology (54.72%)

What are the most cited papers published in the journal?

• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. (523 citations)
• Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer (429 citations)
• The Global Breast Cancer Burden: Variations in Epidemiology and Survival (383 citations)

Research areas of the most cited articles at Clinical Breast Cancer:

The most cited publications generally zeroe in on subjects such as Breast cancer, Internal medicine, Oncology, Metastatic breast cancer and Chemotherapy. The Breast cancer studies which were featured in the most cited publications aim to expound on the research in Cancer. While the journal papers focused on Oncology, they were also able to explore topics like Neoadjuvant therapy, Survival rate, Neutropenia, Paclitaxel and Radiation therapy.

What topics the last edition of the journal is best known for?

• Cancer
• Internal medicine
• Surgery

The previous edition focused in particular on these issues:

The primary areas of discussion in Clinical Breast Cancer are Breast cancer, Internal medicine, Oncology, Cancer and Radiology. The research on Breast cancer featured in Clinical Breast Cancer combines topics in other fields like Radiation therapy, Surgery and Chemotherapy. The journal explores issues in Surgery which can be linked to other research areas like Breast reconstruction and Breast surgery.

The work on Oncology tackled in the journal brings together disciplines like Stage (cooking), Triple-negative breast cancer, Trastuzumab and Cohort. Some problems in Cancer that were presented in the journal overlapped with concepts under Quality of life, Proportional hazards model and Anxiety. Clinical Breast Cancer explores topics in Radiology which can be helpful for research in disciplines like Ductal carcinoma, Mammography and Lymph node.

The most cited articles from the last journal are:

• Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. (29 citations)
• The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer (10 citations)
• Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. (9 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Clinical Breast Cancer (based on the number of publications) are:

• Joyce O'Shaughnessy (82 papers) published 2 papers at the last edition the same number as at the previous edition,
• George W. Sledge (52 papers) absent at the last edition,
• Denise A. Yardley (26 papers) absent at the last edition,
• Gabriel N. Hortobagyi (24 papers) absent at the last edition,
• Clifford A. Hudis (22 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Clinical Breast Cancer (based on the number of publications) are:

• University of Texas MD Anderson Cancer Center (87 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Harvard University (66 papers) published 8 papers at the last edition, 1 more than at the previous edition,
• Memorial Sloan Kettering Cancer Center (54 papers) published 2 papers at the last edition the same number as at the previous edition,
• Mayo Clinic (46 papers) published 6 papers at the last edition, 4 more than at the previous edition,
• University of California, San Francisco (37 papers) published 2 papers at the last edition, 3 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 10.71% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 15.00% were posted by at least one author from the top 10 institutions publishing in the journal. Another 6.00% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 17.00% of all publications and 62.00% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

How Clinical Breast Cancer Research Contributes to Nursing Education

Pursuing education in the nursing field, particularly in advanced specializations like oncology nursing, necessitates a solid grounding in research work such as those featured in Clinical Breast Cancer. Processing the research articles, understanding the methodologies used, and taking away results and conclusions can equip aspiring oncologists with the skills needed to contribute to the field. This highlights the importance of incorporating research-led learning into nursing education and perhaps seeking offerings from top-in-class institutions.

In line with this, those aspiring to be at the forefront of healthcare, particularly within the field of oncology nursing, might find value in exploring some of the best online nursing programs in Texas. This way, they not only gain essential nursing skills, but also an in-depth understanding of crucial research topics which can significantly aid their future dealings within the healthcare system.

Moreover, with researches like those highlighted in Clinical Breast Cancer, the link between research and practical nursing education becomes more evident, reinforcing the need for academic institutions to continuously adapt their curriculum in line with the fast-evolving healthcare landscape.